Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Down 36.9% in March

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 1,250,000 shares, a decline of 36.9% from the February 28th total of 1,980,000 shares. Based on an average daily volume of 2,640,000 shares, the short-interest ratio is currently 0.5 days. Approximately 2.6% of the company’s stock are short sold.

Institutional Trading of Cardio Diagnostics

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC increased its position in Cardio Diagnostics by 97.6% in the 4th quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock worth $334,000 after purchasing an additional 179,978 shares during the last quarter. Two Sigma Securities LLC bought a new stake in shares of Cardio Diagnostics in the 4th quarter valued at approximately $48,000. Jane Street Group LLC acquired a new position in Cardio Diagnostics in the fourth quarter worth approximately $103,000. Finally, Millennium Management LLC acquired a new position in Cardio Diagnostics in the fourth quarter worth approximately $236,000. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Cardio Diagnostics Stock Down 13.4 %

CDIO stock traded down $0.05 during midday trading on Monday, reaching $0.33. The company had a trading volume of 1,096,507 shares, compared to its average volume of 2,529,280. The company has a 50 day moving average of $0.48 and a two-hundred day moving average of $0.48. Cardio Diagnostics has a 1 year low of $0.19 and a 1 year high of $1.77.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.